Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 2898-2905

  Petraitis, Vidmantas ^a   Petraitiene, Ruta ^a   Groll, Andreas H ^a   Bell, Aaron ^a   Callender, Diana P ^a   Sein, Tin ^a   Schaufele, Robert L ^a   McMillian, Carl L ^b   Bacher, John ^c   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B; ANIDULAFUNGIN; CREATININE; ECHINOCANDIN B DERIVATIVE;

ANIMAL MODEL; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS FUMIGATUS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; LUNG ASPERGILLOSIS; LUNG INJURY; LUNG WEIGHT; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RABBIT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031783659     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.2898     Document Type: Article

References (30)

1. Allende, M. C., J. W. Lee, P. Francis, K. Garrett, H. Dollenberg, J. Berenguer, C. A. Lyman, P. A. Pizzo, and T. J. Walsh. 1994. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob. Agents Chemother. 38: 518-522.
2. Berenguer, J., M. C. Allende, J. W. Lee, K. Garrett, C. Lyman, N. M. Ali, J. Bacher, P. A. Pizzo, and T. J. Walsh. 1995. Pathogenesis of invasive pulmonary aspergillosis during persistent granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am. J. Resp. Crit. Care Med. 152:1079-1086.
3. Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
4. Debono, M., W. W. Turner, L. M. LaGrandeur, R. M. Molloy, F. J. Burkhardt, M. Rodriguez, M. J. Zweifel, J. S. Nissen, K. Clingerman, R. S. Gordee, D. J. Zeckner, T. R. Parr, and J. Tang. 1993. LY303366 - a new semi-synthetic lipopeptide antifungal agent related to echinocandin B. Synthetic and structure activity studies, abstr. 359, p. 185. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. Debono, M., W. W. Turner, L. LaGrandeur, F. J. Burkhardt, J. S. Nissen, K. K. Nichols, M. J. Rodriguez, M. J. Zweifel, D. J. Zeckner, R. S. Gordee, J. Tang, and T. R. Parr, Jr. 1995. Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. J. Med. Chem. 38:3271-3281.
6. Denning, D. W., and D. A. Stevens. 1991. Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 35:1329-1333.
7. Ernst, M. E., M. E. Klepser, E. J. Wolfe, and A. Pfaller. 1996. Antifungal dynamics of LY303366, an investigational echinocandin B analog, against Candida ssp. Diagn. Microbiol. Infect. Dis. 26:125-131.
8. Espinel-Ingroff, A., M. Bartlett, R. Bowden, N. X. Chin, C. Cooper, Jr., A. Fothergill, M. R. McGinnis, P. Menezes, S. A. Messer, P. W. Nelson, F. C. Odds, L. Pasarell, J. Peter, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, G. S. Shankland, T. J. Walsh, and I. Weitzman. 1997. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J. Clin. Microbiol. 35:139-143.
9. Francis, P., J. W. Lee, A. Hoffman, J. Peter, A. Francesconi, J. Bacher, J. Shelhamer, P. A. Pizzo, and T. J. Walsh. 1994. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J. Infect. Dis. 169:356-368.
10. Fromtling, R. A. 1994. LY303366. Drugs Future 19:338-342.
11. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed., p. 455-459. Marcel Dekker, New York, N.Y.
12. Gordee, R. S., D. J. Zeckner, L. F. Ellis, A. L. Thakkar, and L. C. Howard. 1984. In vitro and in vivo anti-Candida activity and toxicology of LY121019. J. Antibiot. (Tokyo) 37:1054-1065.
13. Gordee, R. S., D. J. Zeckner, L. C. Howard, W. E. Alborn, Jr., and M. Debono. 1988. Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic. Ann. N. Y. Acad. Sci. 544: 294-309.
14. Huang, A., F. Edwards, E. M. Bernard, D. Armstrong, and H. J. Schmitt. 1990. In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species. Eur. J. Clin. Microbiol. Infect. Dis. 9:697-699.
15. Kurtz, M. B., and C. M. Douglas. 1997. Lipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol. 35:79-86.
16. Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob. Agents Chemother. 38:1480-1489.
17. Lee, J. W., M. A. Amantea, P. A. Francis, E. E. Navarro, J. Bacher, P. A. Pizzo, and T. J. Walsh. 1994. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob. Agents Chemother. 38:713-718.
18. Pannuti, C., R. Gingrich, M. A. Pfaller, C. Kao, and R. P. Wenzel. 1992. Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors. Cancer 69:2653-2662.
19. Petraitiene, R., V. Petraitis, A. Groll, M. Candelario, T. Sein, A. Bell, C. A. Lyman, R. L. Schaufele, and T. J. Walsh. 1998. Efficacy of LY303366, a novel echinocandin, against disseminated candidiasis in persistently neutropenic rabbits, abstr. J-73, p. 472. In Program and abstracts of the 38th Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, in press. American Society for Microbiology, Washington, D.C.
20. Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30:251-255.
21. Pfaller, M. A., S. A. Messer, and S. Coffman. 1997. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob. Agents Chemother. 41:763-766.
22. Uzun, O., S. Kocagoz, Y. Cetinkaya, and S. Unal. 1997. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob. Agents Chemother. 41:1156-1157.
23. Verweij, P. E., K. L. Oakley, J. Morrissey, G. Morrissey, and D. W. Denning. 1997. Efficacy of LY303,366 against amphotericin B "susceptible" and "resistant" A. fumigatus infection in an immunocompromised murine model, abstr. F-73, p. 158. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
24. Walsh, T. J., J. W. Hiemenz, and E. Anaissie. 1996. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect. Dis. Clin. N. Am. 10:365-400.
25. Walsh, T. J., P. Bacher, and P. A. Pizzo. 1988. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab. Anim. Med. 38:467-470.
26. Walsh, T. J., C. McEntee, and D. M. Dixon. 1987. Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. J. Clin. Microbiol. 25:931-932.
27. Walsh, T. J., K. Garrett, E. Feuerstein, M. Girton, M. Allende, J. Bacher, A. Francesconi, R. Schaufele, and P. A. Pizzo. 1995. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob. Agents Chemother. 39:1065-1069.
28. Walsh, T. J., J. W. Lee, P. Kelly, J. Bacher, J. Lecciones, V. Thomas, C. Lyman, D. Coleman, R. Gordee, and P. A. Pizzo. 1991. Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-β-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis. Antimicrob. Agents Chemother. 35:1321-1328.
29. Zeckner, D., T. Butler, C. Boylan, B. Boyll, Y. Lin, P. Raab, J. Schmidtke, and W. Current. 1993. LY303366 activity against systemic aspergillosis and histoplasmosis in murine models, abstr. 364, p. 186. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
30. Zhanel, G. G., J. A. Karlowsky, G. A. Harding, T. V. Balko, S. A. Zelenitsky, M. Friesen, A. Kabani, M. Turik, and D. J. Hoban. 1997. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatilidis, and Aspergillus species. Antimicrob. Agents Chemother. 41:863-865.